Physician profile
Ruben Ramirez
NPI 1700899630
$2,197.61
in general payments reported to CMS, 2019-2025
13 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $317 · 2021: $373 · 2022: $295 · 2023: $135 · 2024: $171 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $909.95 | 2019-2022 | |
| Pfizer INC. | $451.86 | 2019-2025 | |
| Neotract INC. | $255.64 | 2019-2020 | |
| Allergan, INC. | $184.84 | 2019-2020 | |
| Coloplast Corp | $135.64 | 2025 | |
| Myovant Sciences INC. | $54.04 | 2021 | |
| Ferring Pharmaceuticals INC. | $53.78 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $35.88 | 2024 | Provenge |
| Myriad Genetic Laboratories, INC. | $27.42 | 2024 | Prolaris |
| Abbvie INC. | $26.66 | 2021 | |
| Janssen Biotech, INC. | $24.02 | 2019 | |
| Boston Scientific Corporation | $20.57 | 2024 | Rezum Generator |
| Endo Pharmaceuticals INC. | $17.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.